4. Dean GL, Edwards SG, Ives NJ, *et al.* Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. *AIDS* 2002;**16**:75–83.
5. Lawn SD, Myer L, Bekker LG, *et al.* Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. *AIDS* 2007;**21**:335–41.

Renal impairment following aminoglycoside therapy in cystic fibrosis

Cystic fibrosis (CF) is a chronic respiratory, life limiting illness in the Caucasian population. Chronic infection with *Pseudomonas aeruginosa* occurs in more than 80% of adults and this contributes to deterioration in lung function over time.¹ A reported long term complication includes renal impairment from presumed cumulative aminoglycoside antibiotics. Aminoglycosides are highly effective against *Pseudomonas aeruginosa* and effectively penetrate the sputum of patients with CF, achieving more effective bacterial killing.² The nephrotoxicity of aminoglycosides is reported to be caused by proximal tubular alteration of cell function and cell necrosis.³

The study by Smyth *et al*⁴ demonstrates increased renal toxicity measured by plasma creatinine following a case controlled analysis of patients undergoing gentamicin therapy for the treatment of cystic fibrosis exacerbation. The authors did not specify the timing of plasma creatinine measurements in relation to gentamicin dosing (ie, was it collected before the gentamicin dose was given or at an interval following the dose). This would have been important to clarify whether renal impairment was present prior to dosing or occurred subsequently. Of further interest is the measurement of creatinine levels following cessation of gentamicin to elucidate whether renal impairment was persistent or document evidence of renal function recovery. Plasma creatinine reflects glomerular function rather than tubular function, which was not measured in this study. Plasma creatinine levels are subject to factors such as dehydration, nutrition and body size, and may not be a sensitive test in detecting renal impairment until well established disease has occurred.⁵

The challenge in quantifying renal impairment in cystic fibrosis is to describe the site of damage (ie, renal tubules versus renal glomeruli) and manifestations of early injury. Early and more accurate measurements of glomerular filtration rate may be attained by measuring the protein, cystatin C,⁶ or by utilising nuclear medical scans which provide validated measures by renal clearance of exogenous filtration markers, most commonly diethylenetriaminepentaacetate (DTPA).⁷ With regard to tubular injury, excretion of urinary proteins have been proposed as early markers of aminoglycoside induced tubular toxicity. Steinkamp *et al*⁸ demonstrated that acute

tubular injury measured by excretion of urinary enzymes achieve almost complete recovery after 4 weeks from cessation of aminoglycosides. Ideally, prospective studies should measure renal function (both glomerular and tubular) in aminoglycoside naïve cystic fibrosis subjects and document early renal changes following aminoglycoside administration in a dose dependent manner.

A Tai

Correspondence to: Dr A Tai, Department of Respiratory Medicine, Royal Children's Hospital Melbourne, Victoria 3052, Australia; andrew.tai@rch.org.au

Competing interests: None.

Accepted 8 July 2008

REFERENCES

1. Ramsey B. Management of pulmonary disease in patients with cystic fibrosis. *N Engl J Med* 1996;**335**:179–88.
2. Mendelman PM, Smith AL, Levy J, *et al.* Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. *Am Rev Respir Dis* 1985;**132**:761–5.
3. Mingeot-Leclercq MP, Tulkens PM. Aminoglycoside: Nephrotoxicity. *Antimicrob Agents Chemother* 1999;**43**:1003–12.
4. Smyth A, Lewis S, Bertenshaw C, *et al.* Case-control study of acute renal failure in patients with cystic fibrosis in the UK. *Thorax* 2008;**63**:532–5.
5. Brochner-Mortensen J. Current status on assessment and measurement of glomerular filtration rate. *Clin Physiol* 1985;**5**:1–17.
6. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. *Am J Kidney Dis* 2002;**40**:221–6.
7. Gunasekera RD, Allison DJ, Peters AM. Glomerular filtration rate in relation to extracellular fluid volume: similarity between 99mTc-DTPA and inulin. *Eur J Nucl Med* 1996;**23**:49–54.
8. Steinkamp G, Lutge M, Wurster U, *et al.* Renal function in cystic fibrosis: proteinuria and enzymuria before and after tobramycin therapy. *Eur J Pediatr* 1985;**145**:526–31.

Authors' response

We welcome Dr Tai's comments on our paper. We described a case control study of acute renal failure in cystic fibrosis (CF)¹ and not a study designed to measure the prevalence, severity or risk factors for renal impairment. Patients with acute renal failure (ARF) were reported to us from 20 UK CF centres and clinical data were extracted retrospectively from the case notes. We therefore adopted a pragmatic definition of ARF (raised plasma creatinine for age with or without oliguria). We agree that substantial renal impairment may occur before a rise in creatinine is seen. However, our intention was to investigate those patients with renal failure requiring dialysis (needed in 13/24 cases) or close monitoring of renal function.²

In an earlier paper, we have published the maximum plasma creatinine values seen in patients with ARF, recorded after gentamicin, where this was administered (median creatinine 674 mmol/l (range 124–1972)).² At follow-up, 22 of 24 patients had made a

full recovery, with a normal plasma creatinine. One patient required long term dialysis (biopsy evidence of diabetic nephropathy prior to ARF) and another long term antihypertensive treatment.

The design of this study did not allow us to assess whether renal impairment was present prior to ARF. The prevalence of renal impairment in adults with CF is reported as 31–42% but the prevalence in children is unknown.³ We agree that a well designed study of the prevalence and risk factors for renal impairment in children with CF would be useful. We would suggested measuring GFR, using the chromium 51 ethylene diamine tetra acetate (EDTA) test.⁴

Six patients with ARF in our series had biopsy evidence of acute tubular necrosis and two had hypomagnesaemia, which suggests tubular damage.² We have previously shown that there is a smaller elevation in proximal tubular enzymes with once daily tobramycin administration than with traditional three times daily treatment.⁵ Measures of proximal tubular impairment could be included in a future study of renal impairment in children with CF.

A Smyth,¹ C Bertenshaw,² S Lewis,³ I Choonara,¹ A Watson²

¹ Division of Child Health, University of Nottingham, Nottingham, UK; ² Nottingham University Hospitals NHS Trust, Nottingham, UK; ³ Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK

Correspondence to: Dr A Smyth, Clinical Sciences Building, University of Nottingham, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; alan.smyth@nottingham.co.uk

Competing interests: None.

Accepted 11 July 2008

REFERENCES

1. Smyth A, Lewis S, Bertenshaw C, *et al.* A case control study of acute renal failure in cystic fibrosis patients in the United Kingdom. *Thorax* 2008;**63**:532–5.
2. Bertenshaw C, Watson AR, Lewis S, *et al.* Survey of acute renal failure in patients with cystic fibrosis in the UK. *Thorax* 2007;**62**:541–5.
3. Al Aloul M, Miller H, Alapati S, *et al.* Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. *Pediatr Pulmonol* 2005;**39**:15–20.
4. **Administration of Radioactive Substances Advisory Committee.** Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. *Nucl Med Commun* 2000;**21**(Suppl):S1–93.
5. Smyth A, Tan KH, Hyman-Taylor P, *et al.* Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial. *Lancet* 2005;**365**:573–8.

Bronchial asthma on Mount Kilimanjaro is not a disadvantage

Every year, an increasing number of people travel to high altitude and travellers with asthma are becoming more common in remote environments.¹ It is well recognised that certain situations at high altitude, such as exercising in cold air, may provoke symptoms.² However, the mountain

Table 1 Data for 2700 m and 4700 m

	Patients with asthma	Patients without asthma	p Value
2700 m			
RR	16.21 (2.16)	17.91 (7.29)	0.39
HR	90.38 (15.1)	85.41 (13.7)	0.99
SaO ₂	95.50 (2.40)	94.0 (6.10)	0.36
LLS (median (range))	0 (0–7)	0 (0–1)	0.97
Peak flow	563.64 (167.27)	623.29 (188.02)	0.62
4700 m			
RR	16.93 (2.92)	17.95 (3.54)	0.29
HR	98.27 (9.87)	97.94 (15.3)	0.98
SaO ₂	81.93 (6.37)	81.50 (7.36)	0.82
LLS (median (range))	2 (0–7)	3 (0–11)	0.48
Peak flow	623.29 (118.02)	562.06 (171.11)	0.36
Summit day			
LLS (median (range))	6 (0–15)	6 (0–21)	0.98

HR, heart rate; LLS, Lake Louise Score; RR, respiratory rate; SaO₂, arterial oxygen saturation.

environment offers a reduced pollutant and allergen load, potentially causing fewer exacerbations.⁵ Additionally, increased sympathetic tone and adrenocortical output caused by hypoxia counteract bronchospasm. Acetazolamide, used widely by trekkers for the prophylaxis of acute mountain sickness (AMS), has an additional benefit in patients with asthma of reducing airway hyperreactivity.⁴ To our knowledge, this is the first prospective study comparing lung function, physiology and success in mountain summiting among subjects with asthma and their non-asthmatic counterparts.

We studied altitude physiology and the incidence of AMS in tourist trekkers attempting the summit (Uhuru Peak) of Mount Kilimanjaro (5895 m) in August 2005. All subjects gave written informed consent and ethics approval was obtained from the Tanzanian Commission for Science and Technology (2005-261-NA-2005-62). Lake Louise Score for AMS and basic physiological measurements were taken on ascent. All subjects ascended the mountain over 4 or 5 days.

We compared 18 subjects with asthma (nine males, nine females, mean age 30 years (SD 6.2), mean body mass index 22.9 (1.9)) with 291 subjects without asthma (175 males,

116 females, mean age 34.5 (12.3) years, mean body mass index 22.9 (3.2)). Four were taking acetazolamide. Five subjects were controlled with occasional β agonists, six with regular β agonists, two with inhaled steroids and five were unsure of their medication. None declared any comorbidities and two were smokers.

No significant differences were found in any of the physiological parameters between subjects with and without asthma on ascent. There was an increase in peak expiratory flow rate (Micro Plus device; Micro Medical, Chatham, Kent, UK) in patients with asthma at higher altitude, but its significance ($p=0.123$) was limited by underpowering and the fluctuation of readings that meters are subject to at different altitudes.

The incidence of AMS was not different between subjects with and without asthma at any altitude (2700 m: 0/18 vs 3/291, $p=0.665$; 4700 m: 9/16 vs 141/224, $p=0.602$) and there was no difference in summit success (50% of subjects with asthma vs 61% of subjects without asthma, $p=0.523$). No subjects reported any asthma exacerbations.

This study shows that well controlled mild to moderate asthma should not preclude trekkers from attempting to reach high

altitude, does not increase the risk of high altitude illness and does not decrease their chance of reaching the summit. This is similar to trekkers with other chronic diseases.⁵ However, we recognise that these individuals have self-selected; only those with well controlled disease participate in such physical exertion and we are relying on unverified diagnoses. We recommend optimal asthma control before travel, an awareness of the logistics and availability of health care at the destination (including adequate travel insurance), a stock of sufficient medication (including rescue therapy) and, as with all high altitude trips, adequate time for acclimatisation.

S Stokes,^{1,2} N Kalsen,^{2,3} M Earl,^{2,3} H Frost,^{2,3} A G Whitehead,^{2,3} I Tyrrell-Marsh,^{2,4} A Davies^{2,3}

¹ University Hospital of North Staffordshire, Stoke-on-Trent, UK; ² MARS—Manchester Altitude Research Society; ³ Manchester University Medical School, Manchester, UK; ⁴ Hope Hospital, Salford, UK

Correspondence to: Dr S Stokes, c/o Diane Jackson, Clinical Education Centre, University Hospital of North Staffordshire, Stoke-on-Trent ST4 6QG, UK; suzystokes@doctors.org.uk

Competing interests: None.

Ethics approval: Ethics approval was obtained from the Tanzanian Commission for Science and Technology (2005-261-NA-2005-62).

Accepted 13 July 2008

Thorax 2008;**63**:936–937. doi:10.1136/thx.2008.102327

REFERENCES

1. **Cogo A**, Fischer R, Schoene R. Respiratory diseases at altitude. *High Alt Med Biol* 2004;**5**:435–44.
2. **Kaminsky DA**, Irvin CG, Gurka DA, *et al*. Peripheral airways responsiveness to cool, dry air in normal and asthmatic individuals. *Am J Respir Crit Care Med* 1995;**152**:1784–90.
3. **Grootendorst DC**, Dahlen SE, Van Den Bos JW, *et al*. Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma, over and above treatment with high dose inhaled steroids. *Clin Exp Allergy* 2001;**31**:400–8.
4. **O'Donnell WJ**, Rosenberg M, Niven RW, *et al*. Acetazolamide and furosemide attenuate asthma induced by hyperventilation of cold, dry air. *Am Rev Respir Dis* 1992;**146**:1518–23.
5. **Kalsen N**, Davies A, Stokes S, *et al*. Climbers with diabetes do well on Mount Kilimanjaro. *Diabetes Med* 2007;**24**:1496.